Medical/Pharmaceuticals

AIRS Medical Accelerates Global Expansion, Showcasing clinical achievements of MRI Enhancement Solution at RSNA 2023

* Recently achieved MDSAP certification and ISO/IEC 27001, 27017, 27018 certifications, paving the way for accelerated expansion into global markets. * Certified Japan's Pharmaceuticals and Medical Devices Agency (PMDA), signaling the beginning of its full-scale expansion into the Japanese mar...

2023-10-30 23:00 1537

NCCN Expands Focus on Quality of Life and Supportive Care with New Guides for People with Cancer

National Comprehensive Cancer Network publishes free NCCN Guidelines for Patients with information on improving well-being and reducing suffering and distress for people with cancer; available atNCCN.org/patientguidelines. PLYMOUTH MEETING, Pa., Oct. 30, 2023 /PRNewswire/ -- The National Compreh...

2023-10-30 20:37 1465

WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth

* Revenue of RMB10,670 Million in the Third Quarter, Single Quarter Revenue Back to overRMB10 Billion; Revenue of RMB29,541 Million in the First Three Quarters, Up 4.0% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 23.4% * Net Profit Attributable to Owners of the Company for the ...

2023-10-30 20:01 2087

Journal of Thoracic Oncology Published Promising Results of Ivonescimab (PD-1/VEGF Bispecific) as First- or Second-line Therapy for Advanced or Metastatic Immunotherapy Naïve Non-Small-Cell Lung Cancer

HONG KONG, Oct. 30, 2023 /PRNewswire/ -- Akeso (9926.HK) announced that the results of a phase Ib clinical trial for PD-1/VEGF bispecific antibody ( ivonecimab AK112/SMT112 ) as first- or second-line therapy for advanced or metastatic immunotherapy naïve non-small-cell lung cancer (NSCLC) were p...

2023-10-30 20:00 1968

New Clinical Data Point to Use of GlycoMark as Biomarker of SGLT-2 Diabetes Drug Effectiveness and Compliance

RALEIGH, N.C., Oct. 30, 2023 /PRNewswire/ -- Precision Diabetes, Inc. announces new studies that show that the GlycoMark blood test, which measures 1,5-anhydroglucitol, may be useful for evaluating short-term effectiveness and assessing patient compliance of SGLT-2 inhibitor diabetes drugs. SGLT-...

2023-10-30 20:00 1031

Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Announce Collaboration to Develop Herpes Vaccines in China

The partnership will further therapeutic and prophylactic vaccine development for the Chinese market and beyond. WOBURN, Ma. and SHENZHEN, China, Oct. 30, 2023 /PRNewswire/ -- Rational Vaccines (RVx) and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (MH) announced they have reached an agreemen...

2023-10-30 19:30 1319

Aquinnah Pharmaceuticals Advances Oral Small Molecule Program Targeting Alzheimer's and Other Tauopathy Diseases

New preclinical data presented at CTAD demonstrates exciting potential for a new drug approach for Alzheimer's disease, reducing brain tau pathology by ~70% CAMBRIDGE, Mass., Oct. 30, 2023 /PRNewswire/ -- Aquinnah Pharmaceuticals announced preclinical research findings for a novel therapeutic des...

2023-10-30 19:00 1136

Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease

TAIPEI, Oct. 30, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company will be presenting at the American Heart Association (AHA) 2023 Annual Meeting taking place inPhiladelphia, PA, fromNovember 11-13, 2023. The presentation will focus on Foresee...

2023-10-30 15:18 1014

First Patient Enrolled in Phase III Clinical Trial of Boan Biotech's Nivolumab Injection

YANTAI, China, Oct. 30, 2023 /PRNewswire/ -- Boan Biotech (6955.HK) announced today that the first patient in Phase III clinical trial of its Nivolumab Injection (BA1104) inChina has been enrolled. BA1104 is the first biosimilar to Opdivo® to undergo a Phase III study in China. Nivolumab is a mo...

2023-10-30 14:51 1683

Alltech Joins Vital Group to Build an Industry Chain for High-End Medical Imaging

CHENGDU, China, Oct. 30, 2023 /PRNewswire/ -- On Oct. 28th, Alltech, a high-end medical imaging equipment developer under the umbrella of Vital Group, held a press conference titled "Joy of Life, Dream of Innovation" at the 88th China International Medical Equipment Fair (CMEF), where it announce...

2023-10-30 12:35 1914

Linq Wins Samsung Open Collaboration with LLM-Enhanced Underwriting AI Solution

SEOUL, South Korea, Oct. 30, 2023 /PRNewswire/ -- Linq, an AI startup, won first place in the 2023 Samsung Open Collaboration, one of the most prestigious startup competitions inSouth Korea. Linq showcased its AI-powered underwriting solution, which was made possible by its AI risk models and an ...

2023-10-30 08:11 1858

Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

* Mazdutide demonstrates its differentiated advantages as a novel dual agonist of GLP-1 and GCG receptor with superior weight loss efficacy, significant improvement in a series of cardiometabolic indicators (waist circumference, blood pressure, liver enzyme, triglyceride, low-density lipoprote...

2023-10-30 08:00 3350

Samyang Holdings Presents Clinical Cases of 'Lafullen® and Croquis®' at KOAT Academic Conference

* Presentation of "Lafullen®" and "Croquis®" Procedures and Clinical Cases... Confirming Product Excellence and Safety * Biodegradable Polymer Filler "Lafullen®" Maintains Natural Volume for 2 Years * "Croquis®" Lifting Threads with Samyang' expertise in Global Biodegradable Suture Threa...

2023-10-30 08:00 1501

Lunit Enters into Research Collaboration to Explore the Use of AI to Improve the Effectiveness of Immunotherapy

-       Lunit to support MD Anderson researchers studying immune phenotype biomarkers for pembrolizumab treatment response SEOUL, South Korea, Oct. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

2023-10-27 21:07 2913

Everise's Executive Leadership Emerges Winner at OnCon Icon Awards 2023

PLANTATION, Fla., Oct. 27, 2023 /PRNewswire/ -- Everise, a leading global healthcare services outsourcing company, today announced its remarkable achievements at the OnCon Icon Top 100 Awards. The company's commitment to excellence across its workforce and operations has been recognized with mul...

2023-10-27 21:00 3483

Henlius Announces NMPA Approvals of Two ADC Candidates for IND

SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that the investigational new drug (IND) applications of HLX42 for Injection, a novel EGFR-targeting antibody-drug conjugate (ADC) as well as HLX43, a novel PD-L1-targeting ADC, have been approved by the Na...

2023-10-27 20:16 2864

Peijia Medical Presents Early Clinical Findings of GeminiOne® TEER Device at TCT 2023

SUZHOU, China, Oct. 27, 2023 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese medical device player in transcatheter structural heart device and neurovascular device, presented its GeminiOne® TEER technology, along with the early clinical experiences of the device at ...

2023-10-27 20:00 1315

Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India

* The footprint of serplulimab now includes the United States, Europe, Southeast Asia, MENA, and India  * Intas to develop and commercialise serplulimab in Europe and India; Henlius to receive €42 million upfront payment, double-digit royalties and up to €143 million in regulatory and commerc...

2023-10-27 19:47 2246

Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India

* The footprint of serplulimab now includes the United States, Europe, Southeast Asia, MENA, and India * Intas to develop and commercialise serplulimab in Europe and India; Henlius to receive €42 million upfront payment, double-digit royalties and up to €143 million in regulatory and commerci...

2023-10-27 19:13 5574

World Stroke Day: World Stroke Organization calls for Action on Prevention as Global Stroke Mortality is Predicted to Rise by 50%

GENEVA, Oct. 27, 2023 /PRNewswire/ -- The World Stroke Organization (WSO ) is calling on governments and healthcare systems to implement recommendations on stroke prevention set out in the new WSO-Lancet Neurology Commission

2023-10-27 15:00 2343
1 ... 59606162636465 ... 577